secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001818382-25-000122
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte Q2 revenue $0.3M; 82 civilian hospitals now eligible to purchase Symvess; July sales exceed H1 total
--------------------------------------------------------------------------------

- Revenue $0.3M in Q2 (incl $0.1M Symvess sales); $0.8M in H1 2025 vs zero prior year.
- 82 civilian hospitals eligible to purchase Symvess (up from 5 in May); 13 VAC approvals covering multi-hospital networks.
- ECAT approval makes Symvess available to ~35 Military Treatment Facilities and ~160 VA hospitals; first military sale in July followed by re-order.
- Implemented workforce reduction of 30 employees; expects net savings ~$13.8M in 2025 and ~$38M in 2026.
- Cash, cash equivalents, restricted cash $88.4M as of June 30; net cash used $6.9M in H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000181838225000122/0001818382-25-000122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000181838225000122/huma-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001818382-25-000122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer